Table 2.
Decline in Lung Function Based on Baseline Calprotectin Level
Quintile 1 | Quintile 2 | Quintile 3 | Quintile 4 | Quintile 5 | Per Twofold Increment in Baseline Calprotectin | P Value | |
---|---|---|---|---|---|---|---|
Median calprotectin, μg/ml | 4.9 | 6.6 | 10.9 | 16.7 | 24.2 | — | — |
FEV1, ml | |||||||
Unadjusted | −35 | 84 | 0 | 186 | 68 | 33 (–2 to 68) | 0.06 |
Adjusted* | −59 | 66 | −51 | 195 | 65 | 44 (3 to 84) | 0.03 |
FVC, ml | |||||||
Unadjusted | −14 | 54 | −22 | 134 | 175 | 51 (21 to 81) | <0.001 |
Adjusted* | −78 | −17 | −122 | 88 | 89 | 50 (12 to 87) | 0.009 |
The rate of lung function decline per year increases with increasing baseline calprotectin. Data are presented for both unadjusted and adjusted (for age, sex, previous exacerbation rate, symptom score, and high-sensitivity CRP).
Note that three patients did not have a baseline high-sensitivity CRP model and were excluded from the analysis for this model.